Search the Newsreel

Fortis Group Advisors LLC Has $3.50 Million Stake in Novo Nordisk A/S $NVO

Novo Nordisk A/S Target of Unusually High Options Trading (NYSE:NVO)

Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks?

Two healthcare players, Scholar Rock Holding Corporation (NASDAQ:SRRK) and Novo Nordisk A/S (NYSE:NVO), find their near-term narratives intertwined over manufacturing compliance. One is smoothly navigating a supply chain hurdle ahead of a critical drug approval, while the other just delivered a complicated financial quarter. …

Jim Cramer Reevaluates Novo Nordisk (NVO) as Wegovy Pill Adoption Accelerates

Shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) experienced sharp volatility following its latest quarterly results. On the August 12 episode of Mad Money, Jim Cramer pointed out the disconnect between the company's strong performance and Wall Street's initial negative knee-jerk reaction. Cramer …

Signaturefd LLC Buys 22,148 Shares of Novo Nordisk A/S $NVO

Saratoga Research & Investment Management Sells 200,320 Shares of Novo Nordisk A/S $NVO

Mirae Asset Global Investments Co. Ltd. Increases Stake in Novo Nordisk A/S $NVO

QV Investors Inc. Acquires 81,870 Shares of Novo Nordisk A/S $NVO

Exchange Traded Concepts LLC Cuts Stock Holdings in Novo Nordisk A/S $NVO

Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race

Novo Nordisk's stock slipped by approximately 1% after CEO Mike Doustdar reframed the obesity treatment market, emphasizing that it's not a winner-takes-all scenario against Eli Lilly. Doustdar highlighted Novo's strong position in the oral GLP-1 market with oral Wegovy and suggested that pills could …

Novo Nordisk Escalates Weight-Loss War With Eli Lilly

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker's lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead …

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely …

Plano&Plano (PLPL3): Expansão da receita compensada por margens mais fracas

Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the …

Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?

Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for type II diabetes (T2D) and Wegovy for chronic weight management. However, the company's core franchise is facing mounting competitive pressure from Eli Lilly LLY, despite …

Why Novo Resources Corp stock is skyrocketing today

Novo Nordisk A/S (NYSE:NVO) Raised to "Hold" at Zacks Research

Novo Nordisk CEO Doustdar says obesity drugs market won't be dominated by one player

Novo Nordisk CEO Mike Doustdar stated his belief that the obesity drug market, particularly for GLP-1s, will not be a winner-takes-all scenario. He anticipates that consumers will continue to seek various options for weight loss. This outlook suggests a competitive landscape rather than a …

Myriad Asset Management Advisors LLC Purchases Shares of 38,512 Novo Nordisk A/S $NVO

Marshall Financial Group LLC Sells 29,354 Shares of Novo Nordisk A/S $NVO

Altrafin AG Sells 34,450 Shares of Novo Nordisk A/S $NVO

MELK3 - Melnick - Resultados, Dividendos, Cotação e Indicadores

Melnick (MELK3): Lucro acima das estimativas apesar da desaceleração da receita

Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'

Novo Nordisk CEO Mike Doustdar defended the company's lawsuit against Eli Lilly, asserting that competition must be fair and patients deserve full transparency regarding weight-loss drug efficacy. The lawsuit alleges Lilly's advertising for its GLP-1 drugs misleads consumers by comparing them to an older, …

Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps

Novo Nordisk's CEO Mike Doustdar admitted that Eli Lilly is gaining market share in the GLP-1 drug market, leading to a slump in Novo's stock despite positive news like raised full-year sales guidance. Doustdar explained that price cuts for Ozempic and Wegovy to increase …

Novo Nordisk (NVO) Stock Still Looks Cheap On Earnings But Faces Growth Doubts

NVO Stock Price Prediction 2025-2026 | Novo Nordisk A/S Forecast

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 …

Novo Nordisk CEO sees ‘long runway’ for weight-loss drugs as obesity grips America

Novo Nordisk CEO Mike Doustdar believes there is a significant future for weight-loss drugs like Wegovy, as only a small percentage of eligible Americans currently use GLP-1 medications despite over 100 million suffering from obesity. Doustdar highlighted that wider adoption of these drugs could …

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity …

The Market Is (Still) Underestimating Novo Nordisk (NYSE:NVO)

Berenberg Bank Downgrades Novo Nordisk A/S (NYSE:NVO) to Hold

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development …